Oxtriphylline
- TRADE NAMES: Choledyl (Pfizer); Choledyl SA (Warner Chilcott); Oxtriphylline Pediatric; Theobret
- INDICATIONS: Asthma, chronic bronchitis, emphysema, bronchospastic disorders
- CLASS: Bronchodilator
- HALF-LIFE: 1–9 hours in pediatric patients; 3–15 hours in non-smoking adults; 4–5 hours in cigarette smokers
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aminoglutethimide, Carbamazepine, Cimetidine, Ciprofloxacin, Clarithromycin, Disulfiram, Enoxacin, Erythromycin, Estradiol, Estrogens, Febuxostat, Fluvoxamine, Isoproterenol, Methotrexate, Mexiletine, Moricizine, Norfloxacin, Ofloxacin, Phenobarbital, Phenytoin, Propranolol, Rifampin, Sucralfate, Tacrine, Ticlopidine, Verapamil
PREGNANCY CATEGORY: C
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
